DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. More Details
No risks detected for DIA from our risk checks.
Flawless balance sheet with outstanding track record.
Share Price & News
How has DiaSorin's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DIA is not significantly more volatile than the rest of Italian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DIA's weekly volatility (5%) has been stable over the past year.
7 Day Return
IT Medical Equipment
1 Year Return
IT Medical Equipment
Return vs Industry: DIA underperformed the Italian Medical Equipment industry which returned 25.8% over the past year.
Return vs Market: DIA underperformed the Italian Market which returned 32.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is DiaSorin's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWill Weakness in DiaSorin S.p.A.'s (BIT:DIA) Stock Prove Temporary Given Strong Fundamentals?
1 month ago | Simply Wall StDoes DiaSorin (BIT:DIA) Deserve A Spot On Your Watchlist?
1 month ago | Simply Wall StDiaSorin S.p.A.'s (BIT:DIA) 0.7% Dividend Yield Looks Pretty Interesting
Is DiaSorin undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DIA (€141.2) is trading above our estimate of fair value (€88.06)
Significantly Below Fair Value: DIA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DIA is good value based on its PE Ratio (31.2x) compared to the XE Medical Equipment industry average (51.1x).
PE vs Market: DIA is poor value based on its PE Ratio (31.2x) compared to the Italian market (21.7x).
Price to Earnings Growth Ratio
PEG Ratio: DIA is poor value based on its PEG Ratio (18.9x)
Price to Book Ratio
PB vs Industry: DIA is overvalued based on its PB Ratio (8.1x) compared to the XE Medical Equipment industry average (5.2x).
How is DiaSorin forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DIA's forecast earnings growth (1.6% per year) is below the savings rate (1.8%).
Earnings vs Market: DIA's earnings (1.6% per year) are forecast to grow slower than the Italian market (18.9% per year).
High Growth Earnings: DIA's earnings are forecast to grow, but not significantly.
Revenue vs Market: DIA's revenue (2.7% per year) is forecast to grow slower than the Italian market (2.8% per year).
High Growth Revenue: DIA's revenue (2.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DIA's Return on Equity is forecast to be low in 3 years time (16.4%).
How has DiaSorin performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DIA has high quality earnings.
Growing Profit Margin: DIA's current net profit margins (28.1%) are higher than last year (24.9%).
Past Earnings Growth Analysis
Earnings Trend: DIA's earnings have grown by 15.5% per year over the past 5 years.
Accelerating Growth: DIA's earnings growth over the past year (41.1%) exceeds its 5-year average (15.5% per year).
Earnings vs Industry: DIA earnings growth over the past year (41.1%) exceeded the Medical Equipment industry 5.3%.
Return on Equity
High ROE: DIA's Return on Equity (26%) is considered high.
How is DiaSorin's financial position?
Financial Position Analysis
Short Term Liabilities: DIA's short term assets (€713.9M) exceed its short term liabilities (€160.2M).
Long Term Liabilities: DIA's short term assets (€713.9M) exceed its long term liabilities (€129.9M).
Debt to Equity History and Analysis
Debt Level: DIA is debt free.
Reducing Debt: DIA currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: DIA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: DIA has no debt, therefore coverage of interest payments is not a concern.
What is DiaSorin current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: DIA's dividend (0.71%) isn’t notable compared to the bottom 25% of dividend payers in the Italian market (1.33%).
High Dividend: DIA's dividend (0.71%) is low compared to the top 25% of dividend payers in the Italian market (3.91%).
Stability and Growth of Payments
Stable Dividend: DIA is not paying a notable dividend for the Italian market, therefore no need to check if payments are stable.
Growing Dividend: DIA is not paying a notable dividend for the Italian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DIA is not paying a notable dividend for the Italian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DIA's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carlo Rosa (54 yo)
Mr. Carlo Rosa has been the Chief Executive Officer of DiaSorin S.p.A. since 2006 and has been its General Manager since April 27, 2010 also its Executive Director since March 26, 2007. In 2001, Mr. Rosa l...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Carlo's total compensation is reasonable compared to companies of similar size in the Italian market.
Compensation vs Earnings: Carlo's compensation has been consistent with company performance over the past year.
Experienced Management: DIA's management team is seasoned and experienced (5 years average tenure).
Experienced Board: DIA's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
DiaSorin S.p.A.'s company bio, employee growth, exchange listings and data sources
- Name: DiaSorin S.p.A.
- Ticker: DIA
- Exchange: BIT
- Founded: 1968
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €7.533b
- Shares outstanding: 54.70m
- Website: https://www.diasoringroup.com
Number of Employees
- DiaSorin S.p.A.
- Via Crescentino
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for i...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/05 17:48|
|End of Day Share Price||2021/05/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.